Search results for "antibody-dependent cellular cytotoxicity"

showing 1 items of 1 documents

Characterization of zolbetuximab in pancreatic cancer models

2018

ABSTRACT In healthy tissue, the tight junction protein Claudin 18.2 (CLDN18.2) is present only in the gastric mucosa. Upon malignant transformation of gastric epithelial tissue, perturbations in cell polarity lead to cell surface exposure of CLDN18.2 epitopes. Moreover, CLDN18.2 is aberrantly expressed in malignancies of several other organs, such as pancreatic cancer (PC). A monoclonal antibody, zolbetuximab (formerly known as IMAB362), has been generated against CLDN18.2. In a phase 2 clinical trial (FAST: NCT01630083), zolbetuximab in conjunction with chemotherapy prolonged overall and progression-free survival over chemotherapy alone and improved quality of life. In this study, the mech…

0301 basic medicinelcsh:Immunologic diseases. AllergyImmunologyCellclaudin 18.2pancreatic cancerlcsh:RC254-282Malignant transformation03 medical and health sciences0302 clinical medicinePancreatic cancermedicineImmunology and AllergyCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchAntibody-dependent cell-mediated cytotoxicityChemistryimab362medicine.diseasetargeted therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensComplement-dependent cytotoxicity030104 developmental biologymedicine.anatomical_structureOncologyadccCell culturemonoclonal antibody030220 oncology & carcinogenesisCancer researchimmunotherapyzolbetuximablcsh:RC581-607Ex vivoantibody-dependent cellular cytotoxicityOncoImmunology
researchProduct